Biogen stock could pop Thursday after the biotech company beat first-quarter expectations, including strong sales for two newcomer drugs.

Biogen is aiming to expand across the West Coast and is planning to open a hub in South San Francisco. Good news for Bay Area ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.

"'Open innovation' is our word now — open innovation from wherever it comes," said research head Jane Grogan. Bay Area Biotech Forum The Future of Bay Area Biotech: Searching For Answers C-Suite ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 08, 2025 ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Shares of Biogen Inc. BIIB slipped 4.09% to $116.82 Tuesday, on what proved to be an all-around grim trading session for the ...